No abstract

No abstract

No abstract

BackgroundCyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen includes a high dose of prednisolone (100 mg/body), which exhibits an anticancer and antiemetic effect. However, its optimal use for antiemetic therapy has not been established yet. We assessed the efficacy of granisetron plus aprepitant versus granisetron for CHOP or rituximab-CHOP (R-CHOP) regimen-induced nausea and vomiting in malignant lymphoma.MethodsThis retrospective and observational clinical study included patients who received CHOP or R-CHOP regimen as initiating chemotherapy between July 2010 and March 2016 (N = 39). Patients were assigned to an aprepitant [aprepitant (125 mg on day 1, 80 mg on days 2–3) plus granisetron (3 mg); n = 15] or control regimen group [granisetron (3 mg); n = 24]. Complete response (CR), defined as no vomiting and no use of rescue therapy during overall phase (0–120 h), was the primary endpoint. Secondary endpoints included the time to first vomiting and using rescue medication and complete protection (CP) defined as no vomiting and no retching and/or no nausea and no rescue therapy. The patient records were investigated, and data were retrospectively analyzed.ResultsCR rate CP rates did not significantly differ between the groups during the observation period (80.0% versus 83.3%, p = 1.000; and 80.0% versus 79.2%, p = 1.000, respectively). Additionally, the time to first vomiting and using rescue medication in did not significantly differ between the groups (p = 0.909).ConclusionsThis study suggests that granisetron alone could be one treatment option in the management of CINV in patients with non-Hodgkin lymphoma receiving CHOP or R-CHOP regimen.

Stomatitis is one of the most common side effects caused by anticancer agents. Serious stomatitis leads to eating disorders and deteriorates quality of life significantly. However, no effective treatment has been established. Both sodium azulene sulfonate and tranexamic acid are generally used for stomatitis. Here, we aimed to assess the mouthwash containing these two drugs (A + T mouthwash) for the treatment of chemotherapy-induced stomatitis. In this study, we retrospectively investigated the grade of stomatitis (Common Terminology Criteria for Adverse Events version 4.0) and subjective symptom before and after the use of A + T mouthwash in cancer patients receiving chemotherapy, and assessed the ef cacy of A + T mouthwash against chemotherapy-induced stomatitis.Forty-four cancer patients (gastric, colon, cholecystitis, breast, ovarian and unknown primary cancer) were included in this study. The severity of stomatitis was signi cantly improved after using A + T mouthwash compared to before using it (P < 0.05). Of the 44 patients, the grade was improved in 25 patients (56.8 ) and the subjective symptom was improved in 36 patients (81.8 ). These results suggest that A + T mouthwash is effective for chemotherapy-induced stomatitis.